Stereotactic Radiotherapy for Wet AMD (STAR) (STAR)
StereoTactic Radiotherapy for Wet Age-Related Macular Degeneration (STAR): A Randomised, Double-masked, Sham-controlled, Clinical Trial Comparing Low-voltage X-ray Irradiation With as Needed Ranibizumab, to as Needed Ranibizumab Monotherapy.
Sponsor: King's College Hospital NHS Trust
A PHASE3 clinical study on Neovascular (Wet) Age-related Macular Degeneration (AMD), this trial is completed. The trial is conducted by King's College Hospital NHS Trust and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
Status: Unknown → Completed
-
Aug 2025 — Sep 2025 [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
May 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- King's College Hospital NHS Trust
- King's College London
For direct contact, visit the study record on ClinicalTrials.gov .